AstraZeneca's Enhertu gets broader EU approval for breast cancer

July 19, 2022

FILE PHOTO: AstraZeneca’s cancer medicine Enhertu, a drug developed jointly with Japan’s Daiichi Sankyo, is pictured in an undated handout image obtained by Reuters on June 27, 2022. AstraZeneca/Handout via REUTERS

(Reuters) – AstraZeneca said on Tuesday its cancer drug Enhertu was approved in the European Union for treating an aggressive form of breast cancer characterised by a high rate of the protein HER2, widening the therapy’s indications for use in the region.

The approval of the treatment, developed along with Japan’s Daiichi Sankyo, for earlier use in HER2-positive metastatic breast cancer, follows an endorsement by the European Medicines Agency last month.

Source: Read Full Article

What is activated charcoal used for, and does it really work?

Mortality Down for Cancer Patients With Medicaid Expansion

Cybersecurity pressures grow for hospitals as digital health tools multiply